Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Higher export sales of amino acids, strong sales of polymer materials, lower sales of certain active pharmaceutical ingredients and active pharmaceutical ingredient intermediates, higher cost of sales, and recognition of a ¥230 million gain on the sale of investment securities.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥4,284 million (YoY +7.2%) |
| Operating profit | ¥41 million (YoY -69.4%) |
| Ordinary income | ¥45 million (YoY -64.5%) |
| Profit attributable to owners of the parent | ¥200 million (YoY +108.3%) |
| Net income per share | ¥9.26 |
| Equity ratio | End of the current fiscal period 51.9 / End of previous period 52.4 |
| Total assets | ¥25,794 million |
| Net assets | ¥13,385 million |
| Full-year earnings forecast | Net Sales ¥16,000 million (YoY +3.6%) / Operating profit ¥550 million (YoY +43.3%) / Ordinary income ¥500 million (YoY +64.8%) / Net income ¥600 million (YoY +91.5%) / Net income per share ¥27.76 |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥16,000 million / Operating profit To be determined → ¥550 million / Ordinary income To be determined → ¥500 million / Net income To be determined → ¥600 million |
| Annual Dividend Forecast | ¥10 → ¥10（0.0%） |
| Regional sales | Region Domestic / Current fiscal year ¥1,765 million / Prior-year period ¥1,463 million, Region Exports / Current fiscal year ¥2,519 million / Prior-year period ¥2,532 million |
| Depreciation and amortization | ¥304 million |
| Breakdown of extraordinary income (loss) | Gain on sale of investment securities ¥230 million, Loss on Disposal of Fixed Assets ¥9 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 21,974,000 shares |
| Treasury Shares at Period-End | 360,827 shares |
| Factors Behind Changes in Business Performance | Higher export sales of amino acids, strong sales of polymer materials, lower sales of certain active pharmaceutical ingredients and active pharmaceutical ingredient intermediates, higher cost of sales, and recognition of a ¥230 million gain on the sale of investment securities. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased due to higher export sales of amino acids and strong sales of polymer materials, while operating profit declined because of higher cost of sales. Net income increased following the recognition of a ¥230 million gain on the sale of investment securities. Full-year earnings forecasts were disclosed because they were calculated based on reasonable assumptions in light of the latest business environment and earnings trends.